Zacks Research Weighs in on Novavax FY2027 Earnings

Novavax, Inc. (NASDAQ:NVAX - Free Report) - Equities researchers at Zacks Research issued their FY2027 earnings estimates for Novavax in a report released on Thursday, March 20th. Zacks Research analyst S. Ganoria expects that the biopharmaceutical company will post earnings per share of $0.54 for the year. The consensus estimate for Novavax's current full-year earnings is ($1.46) per share.

Novavax (NASDAQ:NVAX - Get Free Report) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.24. The firm had revenue of $88.31 million for the quarter, compared to analysts' expectations of $85.48 million. During the same period last year, the firm earned ($1.44) earnings per share.

Several other equities research analysts also recently weighed in on the company. HC Wainwright restated a "buy" rating and set a $19.00 price target on shares of Novavax in a report on Tuesday, December 10th. BTIG Research began coverage on Novavax in a report on Friday, February 28th. They issued a "buy" rating and a $19.00 price objective on the stock. Finally, TD Cowen raised Novavax to a "hold" rating in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $18.00.

Remove Ads

Novavax Price Performance

Shares of NVAX stock traded down $0.17 during trading hours on Monday, hitting $7.39. The company had a trading volume of 2,892,430 shares, compared to its average volume of 7,984,481. The stock has a market capitalization of $1.19 billion, a PE ratio of -3.27, a price-to-earnings-growth ratio of 2.85 and a beta of 2.92. The company's fifty day moving average is $8.21 and its 200 day moving average is $9.44. Novavax has a fifty-two week low of $3.81 and a fifty-two week high of $23.86.

Insider Transactions at Novavax

In other news, Director James F. Young sold 5,400 shares of the stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total value of $43,200.00. Following the completion of the transaction, the director now owns 51,760 shares of the company's stock, valued at approximately $414,080. This represents a 9.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 1.00% of the company's stock.

Institutional Investors Weigh In On Novavax

Several large investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. purchased a new stake in shares of Novavax in the fourth quarter valued at $27,000. Spire Wealth Management acquired a new stake in Novavax during the 4th quarter worth about $29,000. New Age Alpha Advisors LLC purchased a new position in Novavax during the 4th quarter valued at about $35,000. KBC Group NV grew its position in Novavax by 97.0% during the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company's stock valued at $64,000 after purchasing an additional 3,917 shares in the last quarter. Finally, TigerOak Management L.L.C. acquired a new position in shares of Novavax in the fourth quarter worth $86,000. 53.04% of the stock is owned by institutional investors.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.